Extends fees on over-the-counter drug makers to fund FDA oversight until 2030.
This bill would extend the program that collects fees from companies making over-the-counter (OTC) drugs until 2030. These fees help pay for the Food and Drug Administration's (FDA) work to ensure these drugs are safe and effective. It would also update how these fees are calculated and when they are due.
Today, the FDA collects fees from over-the-counter drug manufacturers under rules set to expire in 2025. After this bill, the FDA would continue to collect these fees until 2030, but with new rules for calculating the amounts, adjusting for various costs, and setting payment deadlines. The bill also clarifies who can represent drug makers when getting advice from the FDA.
HR 4273 · 119th Congress · AI Summary by gemini-2.5-flash · 9/10
Sign in to see your representatives' phone numbers
7 filings mentioned this bill
Amounts reflect total quarterly lobbying spend reported to the Senate, not bill-specific spending. Source: Senate LDA filings.